Special Issue

Radiation Therapy for Pancreatic Cancer

Message from the Guest Editors

Pancreatic cancer is a devastating disease, the third leading cause of cancer-related death in the United States. Nearly 60,000 cases are diagnosed with pancreatic cancer each year in the US, and only less than 10% survive after 5 years. Radiation therapy (RT), as a local–regional anticancer treatment, is an effective way to achieve local control for pancreatic cancer patients. Moreover, dose-escalated RT can significantly increase overall survival rate at 2 years from 19% to 36%, and at 3 years from 9% to 31%; but RT effectiveness is highly limited by adjacent radiosensitive organs at risk. The aim of this Special Issue of *Cancers* on "Radiation Therapy for Pancreatic Cancer" is to highlight both original articles and reviews addressing the current strategies of pancreatic cancer RT, and recent advancements such as image-guided adaptive radiation therapy and artificial-intelligence-based systems to increase the effectiveness of RT for devastating pancreatic cancer.

Guest Editors

Dr. Kai Ding
Johns Hopkins School of Medicine, Baltimore, MD, USA

Dr. Hamed Hooshangnejad
Johns Hopkins School of Medicine, Baltimore, MD, USA

Deadline for manuscript submissions

closed (31 October 2024)

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/si/159144

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/journal/cancers

MDPI

About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)